• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cdk1表达的高核质比预示着结直肠癌患者的预后不良。

High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients.

作者信息

Sung Wen-Wei, Lin Yueh-Min, Wu Pei-Ru, Yen Hsu-Heng, Lai Hung-Wen, Su Tzu-Cheng, Huang Ren-Hung, Wen Chun-Kai, Chen Chia-Yu, Chen Chih-Jung, Yeh Kun-Tu

机构信息

School of Medicine, Chung Shan Medical University, Taichuang, Taiwan.

出版信息

BMC Cancer. 2014 Dec 15;14:951. doi: 10.1186/1471-2407-14-951.

DOI:10.1186/1471-2407-14-951
PMID:25511643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4302138/
Abstract

BACKGROUND

Cdk1 (cyclin-dependent kinase 1) is critical regulator of the G2-M checkpoint. Cyclin-dependent kinase pathways are considered possible targets for cancer treatment; however, the prognostic role of Cdk1 in colorectal cancer is still controversial. Therefore, we attempted to determine the impact of Cdk1 on the clinical outcome of colorectal cancer patients to further identify its role in colorectal cancer.

METHODS

Cdk1 immunoreactivity was analyzed by immunohistochemistry (IHC) in 164 cancer specimens from primary colorectal cancer patients. The medium follow-up time after surgery was 3.7 years (range: 0.01 to 13.10 years). The prognostic value of Cdk1 on overall survival was determined by Kaplan-Meier analysis and Cox proportional hazard models.

RESULTS

All samples displayed detectable Cdk1 expression with predominant location in the cytoplasm and nucleus. A high Cdk1 nuclear/cytoplasmic (N/C) expression ratio was correlated with poor overall survival (5-year survival rate: 26.3% vs 46.9%, N/C ratio ≥1.5 vs N/C ratio <1.5, log-rank p = 0.027). Accordingly, a Cdk1 N/C expression ratio ≥1.5 was identified as an independent risk factor by multivariate analysis (hazard ratio = 1.712, P = 0.039).

CONCLUSIONS

We suggest that Cdk1 N/C expression ratio determined by IHC staining could be an independent prognostic marker for colorectal cancer.

摘要

背景

细胞周期蛋白依赖性激酶1（Cdk1）是G2-M期检查点的关键调节因子。细胞周期蛋白依赖性激酶途径被认为是癌症治疗的潜在靶点；然而，Cdk1在结直肠癌中的预后作用仍存在争议。因此，我们试图确定Cdk1对结直肠癌患者临床结局的影响，以进一步明确其在结直肠癌中的作用。

方法

采用免疫组织化学（IHC）方法分析164例原发性结直肠癌患者癌组织标本中的Cdk1免疫反应性。术后中位随访时间为3.7年（范围：0.01至13.10年）。通过Kaplan-Meier分析和Cox比例风险模型确定Cdk1对总生存期的预后价值。

结果

所有样本均检测到Cdk1表达，主要定位于细胞质和细胞核。Cdk1高核/质（N/C）表达比值与较差的总生存期相关（5年生存率：26.3%对46.9%，N/C比值≥1.5对N/C比值<1.5，对数秩检验p = 0.027）。因此，多因素分析确定Cdk1 N/C表达比值≥1.5为独立危险因素（风险比=1.712，P = 0.039）。

结论

我们认为，通过IHC染色测定的Cdk1 N/C表达比值可能是结直肠癌的独立预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3be9/4302138/e4780ef39d4b/12885_2014_5103_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3be9/4302138/ce4fd03ed984/12885_2014_5103_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3be9/4302138/e4780ef39d4b/12885_2014_5103_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3be9/4302138/ce4fd03ed984/12885_2014_5103_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3be9/4302138/e4780ef39d4b/12885_2014_5103_Fig2_HTML.jpg

相似文献

1
High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients.Cdk1表达的高核质比预示着结直肠癌患者的预后不良。
BMC Cancer. 2014 Dec 15;14:951. doi: 10.1186/1471-2407-14-951.
2
Cytoplasmic, nuclear, and total PBK/TOPK expression is associated with prognosis in colorectal cancer patients: A retrospective analysis based on immunohistochemistry stain of tissue microarrays.细胞质、核和总 PBK/TOPK 表达与结直肠癌患者的预后相关：基于组织微阵列免疫组化染色的回顾性分析。
PLoS One. 2018 Oct 4;13(10):e0204866. doi: 10.1371/journal.pone.0204866. eCollection 2018.
3
The Prognostic Role of STEAP1 Expression Determined via Immunohistochemistry Staining in Predicting Prognosis of Primary Colorectal Cancer: A Survival Analysis.通过免疫组织化学染色测定STEAP1表达在预测原发性结直肠癌预后中的预后作用：一项生存分析
Int J Mol Sci. 2016 Apr 19;17(4):592. doi: 10.3390/ijms17040592.
4
Opposing prognostic roles of nuclear and cytoplasmic RACGAP1 expression in colorectal cancer patients.细胞核和细胞质中RACGAP1表达在结直肠癌患者中的相反预后作用。
Hum Pathol. 2016 Jan;47(1):45-51. doi: 10.1016/j.humpath.2015.09.002. Epub 2015 Sep 21.
5
Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer.细胞质中细胞周期蛋白依赖性激酶1（Cdk1）的积累与上皮性卵巢癌的肿瘤生长和生存率相关。
Oncotarget. 2016 Aug 2;7(31):49481-49497. doi: 10.18632/oncotarget.10373.
6
TGFBI protein high expression predicts poor prognosis in colorectal cancer patients.转化生长因子β诱导蛋白（TGFBI）高表达预示着结直肠癌患者预后不良。
Int J Clin Exp Pathol. 2015 Jan 1;8(1):702-10. eCollection 2015.
7
Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer.联合金属硫蛋白和 p53 蛋白表达作为 Dukes B 和 C 期结直肠癌患者的预后标志物。
Hum Pathol. 2012 Oct;43(10):1695-703. doi: 10.1016/j.humpath.2011.12.014. Epub 2012 Apr 17.
8
Altered subcellular localization of suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas.抑制素是一种新型的细胞周期进入抑制剂，其亚细胞定位改变是结肠腺癌的一个独立预后因素。
Clin Cancer Res. 2001 Nov;7(11):3495-503.
9
Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.核孤儿受体 NR4A2 赋予结直肠癌患者对术后化疗的耐药性，并预测其预后不良。
Eur J Cancer. 2013 Nov;49(16):3420-30. doi: 10.1016/j.ejca.2013.06.001. Epub 2013 Jun 25.
10
Thymidylate synthase and cyclin D1 protein expression in lymph node negative colorectal cancer: role as prognostic factors?胸苷酸合成酶和细胞周期蛋白D1在淋巴结阴性结直肠癌中的蛋白表达：作为预后因素的作用？
Hepatogastroenterology. 2012 Sep;59(118):1859-64. doi: 10.5754/hge10428.

引用本文的文献

1
Gravitational forces and matrix stiffness modulate the invasiveness of breast cancer cells in bioprinted spheroids.重力和基质硬度调节生物打印球体中乳腺癌细胞的侵袭性。
Mater Today Bio. 2025 Mar 4;31:101640. doi: 10.1016/j.mtbio.2025.101640. eCollection 2025 Apr.
2
Cellular Senescence in Hepatocellular Carcinoma: Immune Microenvironment Insights via Machine Learning and In Vitro Experiments.肝细胞癌中的细胞衰老：通过机器学习和体外实验洞察免疫微环境
Int J Mol Sci. 2025 Jan 17;26(2):773. doi: 10.3390/ijms26020773.
3
Combining serum CDK1 with tumor markers for the diagnosis of small cell lung cancer.

本文引用的文献

1
Tumor dissemination: an EMT affair.肿瘤转移：上皮-间质转化事件。
Cancer Cell. 2013 Mar 18;23(3):272-3. doi: 10.1016/j.ccr.2013.03.004.
2
Regulatory networks defining EMT during cancer initiation and progression.在癌症起始和进展过程中定义 EMT 的调控网络。
Nat Rev Cancer. 2013 Feb;13(2):97-110. doi: 10.1038/nrc3447.
3
Cancer statistics, 2013.癌症统计数据，2013 年。
联合血清细胞周期蛋白依赖性激酶1与肿瘤标志物用于小细胞肺癌的诊断。
Clin Transl Oncol. 2025 May;27(5):2005-2013. doi: 10.1007/s12094-024-03722-y. Epub 2024 Oct 13.
4
Integrative Bioinformatics Analysis: Unraveling Variant Signatures and Single-Nucleotide Polymorphism Markers Associated with 5-FU-Based Chemotherapy Resistance in Colorectal Cancer Patients.整合生物信息学分析：揭示与结直肠癌患者基于 5-FU 化疗耐药相关的变异特征和单核苷酸多态性标记物。
J Gastrointest Cancer. 2024 Dec;55(4):1607-1619. doi: 10.1007/s12029-024-01102-x. Epub 2024 Sep 6.
5
Upregulation of lnc-FOXD2-AS1, CDC45, and CDK1 in patients with primary non-M3 AML is associated with a worse prognosis.原发性非M3型急性髓系白血病患者中lnc-FOXD2-AS1、CDC45和CDK1的上调与较差的预后相关。
Blood Res. 2024 Feb 19;59(1):4. doi: 10.1007/s44313-024-00002-0.
6
CSDE1 Intracellular Distribution as a Biomarker of Melanoma Prognosis.CSDE1 细胞内分布作为预测黑色素瘤预后的生物标志物。
Int J Mol Sci. 2024 Feb 15;25(4):2319. doi: 10.3390/ijms25042319.
7
The Cyclin-dependent kinase 1: more than a cell cycle regulator.细胞周期蛋白依赖性激酶 1：不仅仅是细胞周期调控因子。
Br J Cancer. 2023 Nov;129(11):1707-1716. doi: 10.1038/s41416-023-02468-8. Epub 2023 Oct 28.
8
Potential Signature Therapeutic Biomarkers TOP2A, MAD2L1, and CDK1 in Colorectal Cancer: A Systems Biomedicine-Based Approach.结直肠癌潜在的治疗性生物标志物 TOP2A、 MAD2L1 和 CDK1：基于系统生物医学的方法。
Biochem Genet. 2024 Jun;62(3):2166-2194. doi: 10.1007/s10528-023-10544-0. Epub 2023 Oct 26.
9
Hybrid-DIA: intelligent data acquisition integrates targeted and discovery proteomics to analyze phospho-signaling in single spheroids.杂交-DIA：智能数据采集集成靶向和发现蛋白质组学，以分析单个球体中的磷酸化信号。
Nat Commun. 2023 Jun 16;14(1):3599. doi: 10.1038/s41467-023-39347-y.
10
Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer.网络药理学与实验验证探讨康莱特注射液治疗三阴性乳腺癌的作用及机制。
Drug Des Devel Ther. 2023 Mar 23;17:901-917. doi: 10.2147/DDDT.S397969. eCollection 2023.
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
4
Gender difference in the prognostic role of interleukin 6 in oral squamous cell carcinoma.白细胞介素 6 在口腔鳞状细胞癌预后中的性别差异。
PLoS One. 2012;7(11):e50104. doi: 10.1371/journal.pone.0050104. Epub 2012 Nov 21.
5
High expression of interleukin 10 might predict poor prognosis in early stage oral squamous cell carcinoma patients.白细胞介素 10 高表达可能预示早期口腔鳞状细胞癌患者预后不良。
Clin Chim Acta. 2013 Jan 16;415:25-30. doi: 10.1016/j.cca.2012.09.009. Epub 2012 Sep 12.
6
A novel five gene signature derived from stem-like side population cells predicts overall and recurrence-free survival in NSCLC.从类干细胞侧群细胞中提取的新型五基因标志物可预测 NSCLC 的总生存期和无复发生存期。
PLoS One. 2012;7(8):e43589. doi: 10.1371/journal.pone.0043589. Epub 2012 Aug 29.
7
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.BRAF 突变在 III 期结肠癌中的预测和预后作用：CALGB 89803 组间试验的结果。
Clin Cancer Res. 2012 Feb 1;18(3):890-900. doi: 10.1158/1078-0432.CCR-11-2246. Epub 2011 Dec 6.
8
Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer.细胞周期蛋白依赖性激酶 I 的比活性是预测 II 期结肠癌肿瘤复发的一个新的潜在指标。
Br J Cancer. 2012 Jan 3;106(1):133-40. doi: 10.1038/bjc.2011.504. Epub 2011 Nov 22.
9
Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance.细胞质 CDK1 的丢失预示着人类肺癌的不良预后，并赋予其对化疗的耐药性。
PLoS One. 2011;6(8):e23849. doi: 10.1371/journal.pone.0023849. Epub 2011 Aug 24.
10
Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.基于 CDK1 和 CDK2 特定活性的复发风险评分可预测乳腺癌患者对新辅助紫杉醇联合氟尿嘧啶、表柔比星和环磷酰胺的反应。
Ann Oncol. 2012 Apr;23(4):891-7. doi: 10.1093/annonc/mdr340. Epub 2011 Aug 4.